You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • FRI0316 The Efficacy and Safety of Subcutaneous Tocilizumab versus Intravenous Tocilizumab in Combination with Traditional DMARDS in Patients with RA at Week 97 (SUMMACTA)

Citation Tools

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Poster Presentations. Rheumatoid arthritis - other biologic treatment
FRI0316 The Efficacy and Safety of Subcutaneous Tocilizumab versus Intravenous Tocilizumab in Combination with Traditional DMARDS in Patients with RA at Week 97 (SUMMACTA)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Burmester G, Rubbert-Roth A, Cantagrel A, et al
FRI0316 The Efficacy and Safety of Subcutaneous Tocilizumab versus Intravenous Tocilizumab in Combination with Traditional DMARDS in Patients with RA at Week 97 (SUMMACTA)
Annals of the Rheumatic Diseases 2014;73:499-500.